Y-
Y-Biologics
Daejeon KRFounded 201260 employees
Private CapbiotechPrivateOncology
Platform: YBL Bispec
Market Cap
N/A
All Drugs
4
Clinical Trials
6
Failed / Terminated
2
FDA Approved
0
Drug Pipeline (4 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| Sovalemzoparlimab | YB-4926 | Phase 2/3 | 2 | MET | WM | ||
| YB-4895 | YB-4895 | Phase 1/2 | 1 | PARP | RB | ||
| Lisotenlimab | YB-4941 | Phase 1/2 | 2 | DLL3 | AS | ||
| YB-3858 | YB-3858 | Preclinical | 1 | MALT1 | MM |
Financial Documents
This is a private company — SEC filings are not available.
Catalyst Events (6)